Arka Mazumder hails from a middle-class family and had to also take education loans. Now, however, with a lucrative job, he ...

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a year earlier, while its quarterly net loss narrowed to US$108.12 million and ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Recursion Pharmaceuticals ...

In the era of A.I. agents, many Silicon Valley programmers are now barely programming. Instead, what they’re doing is deeply, deeply weird. Credit...Illustration by Pablo Delcan and Danielle Del Plato ...

Recursion Pharmaceuticals is looking to use AI to speed up R&D in the biotech industry. The company has yet to show the value of its approach and faces significant uncertainty. Recursion ...

Shares of early-stage biotech stocks, including Biohaven (NYSE: BHVN), Recursion Pharmaceuticals (NASDAQ: RXRX), and CRISPR Therapeutics (NASDAQ: CRSP), plunged in March, with the stocks down 35.3%, ...

Artificial intelligence (AI) is all the rage on Wall Street these days, but not every AI stock is equally successful. Some of the bigger names in the field, like Nvidia, have seen their shares soar in ...

Recursion Pharmaceuticals’ latest earnings call struck a cautiously optimistic tone as management highlighted its first AI-enabled clinical proof-of-concept, major cost cuts, and an extended cash ...